Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial

Table 2

Clinical data of all STEMI patients at baseline and after 6 months and comparisons between STEMI patients treated with ramipril and losartan after six months of therapy.

Clinical data (mean ± SD)	All; ()	Ramipril; ()	Losartan; ()
NT-proBNP (pg/mL)
Before treatment	222.4 ± 189.1	211.7 ± 181.1	233.9 ± 200.2	0.671
6 months after treatment	40.3 ± 56.1	29.6 ± 21.4	51.0 ± 75.6	0.163
PAI-1 activity (U/mL)
Before treatment	2.8 ± 2.1	2.6 ± 2.1	3.1 ± 2.1	0.408
6 months after treatment	2.8 ± 1.9	2.4 ± 1.8	3.1 ± 1.9	0.163
EF (%)
Before treatment	53.5 ± 9.1	53.5 ± 9.4	53.6 ± 9.0	0.971
6 months after treatment	56.8 ± 8.3	57.0 ± 8.1	56.6 ± 8.5	0.858

Within group analysis: .
NT-proBNP: N-terminal fragment of pro-brain-natriuretic peptide; PAI-1: plasminogen activator inhibitor type 1; EF: ejection fraction.